LDHB and neoplasm: Considering the side effects of lysosomotropic agent chloroquine (Maycotte et al., 2012) and a decrease in chloroquine activity by tumour acidity (Pellegrini et al., 2014), SIRT5‐mediated LDHB deacetylation pathway might be a new therapeutic target for treating CRC.